Immune Response Following Lobectomy Along With or Without Bilateral Transcervical Mediastinal Lymphadenectomy
Immune Response of Patients Following Thoracoscopic Lobectomy Along With Bilateral Transcervical Mediastinal Lymphadenectomy and Patients Receiving VATSLOB Together With Standard Unilateral Mediastinal Lymphadenectomy
1 other identifier
interventional
200
1 country
1
Brief Summary
Any kind of anatomical lung resection for lung cancer with curative intent has to be accompanied by formal mediastinal lymph node dissection. Video-assisted mediastinoscopic lymphadenectomy through a cervical access (VAMLA) along with thoracoscopic lobectomies in the same setting offers improved radicality through bilateral mediastinal dissection, provide accurate staging, does not require single lung ventilation and hence ideally supports the concept of minimally invasive surgery. Due to the VAMLA associated radicality, the investigator believes that using of VAMLA along with lobectomy could improve the oncological outcome of lung cancer patients. Furthermore, the absence of single lung ventilation during VAMLA could attenuate the surgically induced immunosuppression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Oct 2020
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2020
CompletedFirst Submitted
Initial submission to the registry
October 15, 2020
CompletedFirst Posted
Study publicly available on registry
March 3, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2023
CompletedMarch 3, 2021
March 1, 2021
2.2 years
October 15, 2020
March 2, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
postoperative interleukins
Interleukin (IL) 6 serum concentration on the 1st postoperative day
1st postoperative day
Secondary Outcomes (2)
Hospitalisation
until discharge from hospital, assessed up to 14 days
Overall Survival
5 years
Study Arms (2)
Lung Lobectomy with standard ipsilateral lymphadenectomy
ACTIVE COMPARATORLung lobectomy with ipsilateral lymphadenectomy
Lung Lobectomy with VAMLA
ACTIVE COMPARATORLung lobectomy combined with video-assisted mediastinal lymphadenectomy through the neck (VAMLA). The approach is similar to transcervical mediastinoscopy and allows for a radical bloc dissection of all mediastinal lymph node stations. Besides the benefit of bilateral lung ventilation during this phase of the operation a bilateral mediastinal lymphadenectomy offers improved surgical radicality.
Interventions
radical bloc dissection of all mediastinal lymph node stations
Eligibility Criteria
You may qualify if:
- adult
- non small cell lung cancer
- operable tumor
- indicated for endoscopic lung surgery
You may not qualify if:
- pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Otto Wagner Hospitallead
- Medtronic Spine LLCcollaborator
Study Sites (1)
Department of Thoracic Surgery, clinic Floridsdorf
Vienna, 1210, Austria
Related Publications (1)
Salama M, Mueller MR. Enhanced recovery in lung surgery: coaxial versus conventional chest drains following video-assisted thoracoscopic surgery lobectomy-a prospective randomized trial. J Thorac Dis. 2025 Nov 30;17(11):10262-10271. doi: 10.21037/jtd-2025-1169. Epub 2025 Nov 26.
PMID: 41376917DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Micheal Mueller, MD
Department of thoracic Surgery, Clinic Floridsdorf
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
October 15, 2020
First Posted
March 3, 2021
Study Start
October 1, 2020
Primary Completion
December 31, 2022
Study Completion
March 1, 2023
Last Updated
March 3, 2021
Record last verified: 2021-03